Stigmasterol Attenuates Triple-negative Breast Cancer Stem Cell Properties by Inhibiting JAK3

Overview

Journal J Cancer

Specialty Oncology

Date 2025 Feb 24

PMID 39991585

Authors

Ruijuan Zhou

Yuzhu Zhang

Leqin Xu

Yang Sun

Affiliations

Soon will be listed here.

Abstract

Breast cancer stem-like cells (BCSCs) are considered a source of tumor origins, metastasis and drug resistance, thereby limiting current treatment regimens. Stigmasterol has been reported to inhibit various cancer processes, but its effects and mechanisms in BCSCs have not been investigated. To generate spheroids, we enriched parental and SUM159 cells with BCSCs in a serum-free medium. The effects on the stemness, metastasis and drug resistance of CSC-enriched SUM159 cells were detected for the first time by and experiments. CSC-enriched SUM159 and 4T1 cells demonstrated higher potential for tumorigenesis and metastasis. Stigmasterol suppresses BCSCs' spheroid formation, cell viability, and migration ability and promotes cell apoptosis. Stigmasterol also inhibited BCSCs-originated cancer formation in rat models. Stigmasterol also attenuated the growth of TNBC organoids from human breast cancer tissues. These data revealed the inhibitory effects of stigmasterol on BCSC traits. In the meantime, we found that JAK3 was upregulated in BCSCs, and Stigmasterol could effectively inhibit its expression. In addition, JAK3 was evidenced to negatively regulate BCSC activity and stemness both and . More importantly, the results indicated that Stigmasterol suppresses BCSC activity by inhibiting JAK3 expression. This study is the first to demonstrate that Stigmasterol inhibited metastasis and stemness of BCSCs by downregulating JAK3, which might provide a new method for the clinical application of Stigmasterol in breast cancer.

References

Katoh M . Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017; 51(5):1357-1369. PMC: 5642388. DOI: 10.3892/ijo.2017.4129. View

Law M . Plant sterol and stanol margarines and health. West J Med. 2000; 173(1):43-7. PMC: 1070975. DOI: 10.1136/ewjm.173.1.43. View

Tiwari A, Modi S, Gabhe S, Kulkarni V . Evaluation of piperine against cancer stem cells (CSCs) of hepatocellular carcinoma: Insights into epithelial-mesenchymal transition (EMT). Bioorg Chem. 2021; 110:104776. DOI: 10.1016/j.bioorg.2021.104776. View

Guillen K, Fujita M, Butterfield A, Scherer S, Bailey M, Chu Z . A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022; 3(2):232-250. PMC: 8882468. DOI: 10.1038/s43018-022-00337-6. View

Zhao H, Zhang X, Wang M, Lin Y, Zhou S . Stigmasterol Simultaneously Induces Apoptosis and Protective Autophagy by Inhibiting Akt/mTOR Pathway in Gastric Cancer Cells. Front Oncol. 2021; 11:629008. PMC: 7940753. DOI: 10.3389/fonc.2021.629008. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Jiao J, Cheng C, Xu P, Yang P, Zhang K, Jing Y . Mechanisms of pancreatic tumor suppression mediated by Xiang-lian pill: An integrated in silico exploration and experimental validation. J Ethnopharmacol. 2022; 298:115586. DOI: 10.1016/j.jep.2022.115586. View

Sudharsan P, Mythili Y, Sudhahar V, Varalakshmi P . Role of lupeol and its ester on cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats. J Pharm Pharmacol. 2005; 57(11):1437-44. DOI: 10.1211/jpp.57.11.0009. View

Gomez-Arteaga A, Margolskee E, Wei M, Van Besien K, Inghirami G, Horwitz S . Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019; 60(7):1626-1631. PMC: 8162842. DOI: 10.1080/10428194.2019.1594220. View

10.

Bhatia S, Kramer M, Russo S, Naik P, Arun G, Brophy K . Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. Cancer Res. 2022; 82(7):1174-1192. PMC: 9135475. DOI: 10.1158/0008-5472.CAN-21-2807. View

11.

Lin X, Wang F, Chen J, Liu J, Lin Y, Li L . N-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. Mil Med Res. 2022; 9(1):19. PMC: 9008995. DOI: 10.1186/s40779-022-00378-z. View

12.

Mohan C, Rangappa S, Preetham H, Nayaka S, Gupta V, Basappa S . Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. Semin Cancer Biol. 2020; 80:157-182. DOI: 10.1016/j.semcancer.2020.03.016. View

13.

Cheng T, Wang C, Lu Q, Cao Y, Yu W, Li W . Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer. Free Radic Biol Med. 2022; 180:108-120. DOI: 10.1016/j.freeradbiomed.2022.01.010. View

14.

Jeong E, Kim M, Nam H, Min C, Lee S, Chung Y . Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008; 14(12):3716-21. DOI: 10.1158/1078-0432.CCR-07-4839. View

15.

AmeliMojarad M, AmeliMojarad M, Pourmahdian A . The inhibitory role of stigmasterol on tumor growth by inducing apoptosis in Balb/c mouse with spontaneous breast tumor (SMMT). BMC Pharmacol Toxicol. 2022; 23(1):42. PMC: 9208195. DOI: 10.1186/s40360-022-00578-2. View

16.

Bae H, Song G, Lim W . Stigmasterol Causes Ovarian Cancer Cell Apoptosis by Inducing Endoplasmic Reticulum and Mitochondrial Dysfunction. Pharmaceutics. 2020; 12(6). PMC: 7356731. DOI: 10.3390/pharmaceutics12060488. View

17.

Barcia Duran J, Lu T, Houghton S, Geng F, Schreiner R, Xiang J . Endothelial Jak3 expression enhances pro-hematopoietic angiocrine function in mice. Commun Biol. 2021; 4(1):406. PMC: 7994450. DOI: 10.1038/s42003-021-01846-3. View

18.

Choi H, Kim D, Chung H, Park I, Kim B, Oh E . Screening of breast cancer stem cell inhibitors using a protein kinase inhibitor library. Cancer Cell Int. 2017; 17:25. PMC: 5307923. DOI: 10.1186/s12935-017-0392-z. View

19.

Lewis S, Callaway M, Dos Santos C . Clinical applications of 3D normal and breast cancer organoids: A review of concepts and methods. Exp Biol Med (Maywood). 2022; 247(24):2176-2183. PMC: 9899987. DOI: 10.1177/15353702221131877. View

20.

Palomeras S, Ruiz-Martinez S, Puig T . Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance. Molecules. 2018; 23(9). PMC: 6225226. DOI: 10.3390/molecules23092193. View